According to news releases that surfaced in June 2013, Pfizer previously took major steps to protect its embattled Lipitor medication. Among those steps were financial offerings made to insurance companies and others. Pfizer’s financial maneuvers were purportedly designed, in part, to keep other pharmaceutical manufacturers from reducing the beleaguered company’s profit margins. In addition to offering financial incentives to healthcare professionals, the company is accused of raising the drug’s retail prices at the same time.
The retail price increases purportedly took place from 2006 to 2011, which was prior to the public announcement that Lipitor causes diabetes in women. At this juncture, it should be noted that the revelation that Lipitor causes diabetes in women was partially based on studies that took place from 1993 to 2005. A copy of those researchers’ findings were published in a 2012 winter issue of JAMA Internal Medicine.
It isn’t the only time that Pfizer made headlines this year regarding its marketing practices either. In April 2013, it finally settled an aged case connected to the way it promoted the drug Neurontin in the early 2000s. One of the tactics allegedly used by the company at that time was the delayed publication of research indicating that their drug was not all that the company claimed it to be.
This obviously leaves one to query, “Do the most recent allegations that the company attempted to crush the competition and unfairly raise retail prices increase its liability in the ongoing Lipitor cases?” That question presently remains unanswered and is in the hands of the legal system.
With that said, women that have a history of taking Lipitor and developed diabetes are encouraged to contact The Levensten Law Firm to learn how to protect your rights to seek compensation for your injuries. Our mass tort lawyers have experience dealing with drug manufacturers like Pfizer. As such, we can help Lipitor victims negatively impacted by the drug seek reasonable compensation.